SAHPRA raises the bar: What the new clinical guidelines means for Pharma

A New Chapter in South African Medicines Regulation

On 1 June 2026, the South African Health Products Regulatory Authority ("SAHPRA") brought into effect its updated clinical guideline, SAHPGL-CEM-01_V4 (the "SAHPRA Guideline"). For pharmaceutical companies operating in or looking to enter the South African market, this is not a routine administrative update - it is a recalibration of how clinical evidence is assessed, and consequently, how quickly and successfully a product can reach patients.

The SAHPRA Guideline sets out the documentation, data, and scientific evidence SAHPRA expects to see in registration applications for human medicines, and it consolidates the assessment processes applicable to new chemical entities, generic products, extension applications, and applications that rely on the work of other regulators. In short, it is now the primary reference point for any applicant preparing a Category A or Category D registration submission in South Africa.

Companies that align their regulatory strategy with the Guideline's structure stand to benefit from more predictable, and potentially faster, pathways to registration. Those that don't risk delays, additional query rounds, or refusals, all of which carry real commercial cost.

Who Does the Guideline Apply To?

The SAHPRA Guideline applies to human medicines falling within Category A and Category D, as defined in the Medicines and Related Substances Act, 1965, and governs both new registration applications and specified amendments to existing registrations. Any life sciences business with a Category A or D product in its South African pipeline, whether an innovator, generic manufacturer, or licensing partner, should treat the SAHPRA Guideline as required reading before its next submission.

The Four Application Types

The Guideline draws a clear distinction between four categories of application, each carrying its own evidentiary expectations:

1. New Chemical Entity Applications ("NCE"): 

Applications involving active substances that have never been registered in South Africa, including clones. Notably, an active pharmaceutical ingredient not yet registered by SAHPRA will be treated as an NCE regardless of whether it has already been registered by other regulatory authorities. These sit at the top end of the evidentiary scale, generally requiring comprehensive non-clinical and clinical data addressing the proposed indication, dosage regimen, formulation, and overall benefit-risk profile.

2. Generic and Multisource Applications: 

Applications seeking to bring a therapeutic alternative to an already-approved product to market including exact copies, alternative forms of the same medicine (for example, a different salt or tablet form that delivers the same active ingredient), and applications to extend an existing approval. The evidentiary focus here shifts to demonstrating comparable performance to reference medicine - typically through bioequivalence, comparative bioavailability, and dissolution data, supplemented by clinical data where necessary. How much evidence is needed, and how quickly the application is processed, generally depends on whether the reference product is already registered in South Africa or has been approved by trusted regulators overseas.

3. Pharmaceutical Equivalence Applications: 

Applications for products that share the same active ingredient, dosage form, strength, and route of administration as a reference product. Applicants must demonstrate bioequivalence and provide supporting data to confirm therapeutic equivalence. Where a different salt, ester, or similar variant of the active ingredient is used, applicants must also show that this variation doesn't meaningfully affect safety or efficacy.

4. Pharmaceutical Alternatives and Extension Applications: 

Applications for products that deliver the same active ingredients by the same route of administration but differ in dosage form (e.g. tablet vs. capsule) or chemical form (e.g. a different salt or ester). Because such differences can affect the absorption or behaviour of the active ingredient, additional clinical data may be required to confirm that safety and efficacy are not compromised, and therapeutic equivalence to the reference product is not assumed by default.

A failure to correctly identify which category an application falls into, and building the application accordingly from the outset, is a costly and time-consuming pitfall that should be avoided. Miscategorisation can trigger avoidable queries and timeline slippage.

Three Review Pathways, Three Different Strategies

Perhaps the most commercially significant feature of the SAHPRA Guideline is its formalisation of three distinct review pathways. Selecting the right pathway, and building the application to fit it, can materially influence both the speed and predictability of the registration process.

The following review pathways are available under the SAHPRA Guidelines: 

1. Full Review: 

A comprehensive, ground-up assessment of all submitted non-clinical and clinical data, including pharmacology, toxicology, pharmacokinetics, clinical efficacy, safety, and the overall benefit-risk profile. This is the default pathway for genuinely novel products where no comparable prior assessment exists and also applies to biological and biosimilar medicines not yet registered by SAHPRA or a recognised regulatory authority. 

2. Abridged Review: 

Designed to streamline the review of products already approved by a recognised regulatory authority, this pathway allows SAHPRA to leverage prior assessments while maintaining independent regulatory oversight. It applies to select new chemical entities and biological applications, generic applications supported by clinical data, Type II variations, extension applications, and all biosimilars.

3. Verified Review: 

Reserved primarily for multi-source and generic products where the active pharmaceutical ingredient is already registered with SAHPRA. Rather than a full reassessment of clinical evidence, the focus narrows to verifying consistency with the approved reference product information, particularly from a clinical safety standpoint.

For companies with products that have already cleared a stringent overseas regulator, or that are bringing generics of already-registered actives to market, these accelerated pathways can represent a genuine competitive advantage, provided the application is structured from the outset to qualify.

Why This Matters Commercially

Compliance with the SAHPRA Guideline is now a practical prerequisite for successful Category A and Category D registration in South Africa. Applications that are properly matched to the correct application type and review pathway, and that are supported by the appropriate quality, non-clinical, and clinical data, are positioned for a more efficient regulatory assessment and a stronger likelihood of a favourable benefit-risk determination. For manufacturers and pharmaceutical entities, that translates directly into faster, more predictable market entry - and for patients, earlier access to safe and effective medicines.

Conversely, applications that misjudge the applicable pathway, or that are built on an outdated understanding of SAHPRA's evidentiary expectations, risk falling into unnecessary query cycles, resubmissions, or delays that can materially affect launch timelines and commercial planning.